Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLAMO: Artemether-lumefantrine for Non-falciparum Malaria
NCT02528279Completed
- Sponsor
- Albert Schweitzer Hospital
- Start
- Oct 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of artemether + lumefantrine in malaria, sponsored by Albert Schweitzer Hospital. Primary endpoint: Adequate clinical and parasitological response at 28 days. Started Oct 2014; status: completed.
02
Drugs
artemether + lumefantrine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02528279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02528279.